Background and Purpose 20 Microglial inflammatory activity is thought to be a major contributor to the pathology of 21 neurodegenerative conditions such as Alzheimer's disease (AD), and strategies to restrain 22 their behaviour are under active investigation. Classically, anti-inflammatory approaches aim 23 to suppress pro-inflammatory mediator production, but exploitation of inflammatory resolution, 24 the endogenous process whereby an inflammatory reaction is terminated, has not been fully 25 investigated as a therapeutic approach in AD. In this study, we sought to provide proof-of-26 principal that the major pro-resolving actor, formyl peptide receptor 2, Fpr2, could be targeted 27 to reverse microglial activation induced by the AD-associated pro-inflammatory stimulus, 28 oligomeric β-amyloid (oAβ).
H2DCFDA for 20 minutes at 37°C. Following removal of unbound dye, fresh phenol red free-minutes at 37°C in the dark. Cells were washed, fluorescence of non-engulfed particles was 166 quenched by addition of 0.2% Trypan blue (ThermoFisher Scientific, UK) for 1 min, and cellular 167 fluorescence was determined using a FACS Canto II flow cytometer (BD Biosciences, UK) 168 equipped with a 488nm laser and FlowJo 8.8.1 software (Treestar Inc. FL, USA). A total of 169 10,000 singlet events per sample were quantified. 
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Technologies, California, USA) according to the manufacturer's instructions. BV2 cells plated 240 at 2 x 10 6 cells/cm 2 were serum starved overnight and treated according to experimental 241 design. Medium was replaced with Seahorse XF DMEM supplemented with 1 g/L glucose and 242 1 mM sodium pyruvate, pH 7.4 (Sigma, UK) and cells were incubated at 37°C without CO2 for 243 45 min prior to analysis of oxygen consumption rate (OCR) and extracellular acidification rate 244 (ECAR). Basal respiration was initially determined prior to subsequent serial cellular 245 treatments with 4 μM oligomycin, 0.6 μM FCCP and 1 μM rotenone/antimycin A to measure 246 ATP production, maximal respiratory capacity and non-mitochondrial respiration, respectively.
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For each treatment, readings were taken in triplicate every 5 min. Cells were lysed in RIPA 248 buffer and protein content was assessed by Bradford's method for sample normalisation.
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Rates of glycolytic and oxidative ATP production were then calculated as described in [27] . 
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Having previously showing that BV2 cells express murine Fpr2/3 [28], we investigated whether 298 activation of this receptor could reverse oAβ-induced ROS production. Treatment of cells with 299 the Fpr2/3 specific agonist QC1 (100nM), delivered 10 min after oAβ-stimulation restored ROS 300 production to baseline levels ( Figure 2C-2D ). Moreover, this effect was sensitive to pre-301 treatment with the Fpr2/3 specific antagonist WRW4 at 10 µM ( Figure 2E ). Notably, production 302 of ROS in response to oAβ itself was not affected by WRW4 inclusion, indicating that oAβ is 303 not in this case signalling through Fpr2/3 ( Figure 2E ). Confirming these data, measurement of 304 total cellular H2O2 revealed that whilst this species was undetectable in unstimulated cells, 
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In the context of AD however, where no infectious agent has been discovered, production of 
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Future work will determine whether the in vitro findings we report here can be extended to the 391 in vivo situation, but if so, they suggest that the use of Fpr2/3 agonists capable of reversing 392 NADPH oxidase activation may be of therapeutic potential for AD. 
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However, a notable finding of the current work is that we were unable to detect evidence for 415 an oAβ-induced microglial inflammatory response, in contrast to previous in vitro studies 416 [24, 47, 51 ]. This does not appear to be due to deficiency in the BV2 cells themselves, as 417 stimulation with bacterial lipopolysaccharide was still able to trigger a potent inflammatory 418 response. Notably, studies that report pro-inflammatory effects of oAβ have commonly used 419 micromolar concentrations of the peptide, several orders of magnitude greater than levels further validation. Nevertheless, oAb was clearly able to induce ROS production at levels 423 capable of damaging bystander cells, which if replicated in vivo may be a driving factor in 424 ongoing neuronal damage and secondary neuroinflammation seen in AD. Production of ROS 425 is far from the sole damaging effect of oAβ in the brain, as is borne out by the, at best, 426 equivocal results from clinical trials of antioxidants in AD [50, 51] . Nevertheless, targeting a 427 receptor with the potential to suppress ROS production, restore microglial metabolic 428 homeostasis and promote resolution, as is the case for Fpr2/3, has significant potential for 429 therapeutic development.
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The goal of this study was to provide proof-of-principle evidence that exploitation of human 
